Covered in detail in the last edition of Bioshares, Syntara's (SNT: $0.032) wound healing study next year should be a driver for the stock. A study in 20 patients following open chest surgery will compare the company's pan-LOX inhibitor SNT-9645 with a placebo gel.
Each patient can be expected to have similar scars, and each patient will be their own control, applying SNT-9645 and the placebo to different ends of the scar, with a gap in the middle that will receive no cream.
Syntara expects to have five clinical study readouts in 2026. In the first half of next year the company expects Phase I results from another wound healing study in keloid scars (more difficult to treat) being conducted with the earlier version of SNT-9645.
It also expects to have interim results from two Phase Ic studies underway in myelodysplastic syndrome (MDS) with its drug candidate amsulostat. In 2023 the University of Heidelberg in Germany published a link between MDS and LOX enzymes. Most of Syntara's programs are around inhibiting the LOX enzymes.
In February last year a Phase Ic clinical program with the University of Newcastle and the Australasian Leukemia and Lymphoma group started trialing amsulostat following $0.8 million in funding from Australian Medical Research Future Fund. That study is in patients with low risk MDS.
Then in August last year Heidelberg University (Medical Center Mannheim) received $2.5 million in funding from the German government to conduct a Phase I//II study in patients with high risk MDS with amsulostat.
The fifth study to read out next year is with the company's SSAO inhibitor, which was previously licensed to Boehringer Ingelheim and returned to Syntara. A link has been found between SSAO and the onset of Parkinson's and Lewy Bodies dementia. Around 70% of people who go on to develop these disorders show signs of "isolated rapid eye movement sleep disorder". The thought is that giving these people Syntara's drug candidate, SNT-4728, may have a neuroprotective effect and delay or prevent these diseases. The study is being run by the University of Oxford and the University of Sydney, with at least 20 of the target 40 patients enrolled. Results are expected in the first half of next year.
Syntara is capitalized at $51 million with a proforma cash balance of $14.4 million at the end of September.
Disclaimer:
Information contained in this newsletter is not a complete analysis of every material fact respecting any company, industry or security. The opinions and estimates herein expressed represent the current judgement of the publisher and are subject to change. Blake Industry and Market Analysis Pty Ltd (BIMA) and any of their associates, officers or staff may have interests in securities referred to herein (Corporations Law s.849). Details contained herein have been prepared for general circulation and do not have regard to any person’s or company’s investment objectives, financial situation and particular needs. Accordingly, no recipients should rely on any recommendation (whether express or implied) contained in this document without consulting their investment adviser (Corporations Law s.851). The persons involved in or responsible for the preparation and publication of this report believe the information herein is accurate but no warranty of accuracy is given and persons seeking to rely on information provided herein should make their own independent enquiries. Details contained herein have been issued on the basis they are only for the particular person or company to whom they have been provided by Blake Industry and Market Analysis Pty Ltd. The Directors and/or associates declare interests in the following ASX Healthcare and Biotechnology sector securities: Analyst MP: 1AD, ACR, AVR, CGS, CUV, CYC, DXB, IMM, LBT, MX1, OPT, NEU, PAB, PXS,RNO,SOM. These interests can change at any time and are not additional recommendations. Holdings in stocks valued at less than $100 are not disclosed.
